Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

Table 2 Treatment patterns and medical appointments during the follow-up period (Crohn’s disease and ulcerative colitis patients)

	CD patients (n = 118)	UC patients (n = 36)
IBD treatment at index date appointment, n (%)1	111 (94.1)	35 (97.2)
5-ASA derivates	36 (30.5)	33 (91.7)
Corticosteroids	56 (47.5)	21 (58.3)
Immunosuppressants	65 (55.1)	21 (58.3)
Biologics	74 (62.7)	14 (38.9)
Patients who received at least one corticosteroid for ≥ 3 mo, n (%)2	31 (26.3)	18 (50.0)
Treatments at the start of 12-mo follow-up (index date), n (%)
IBD treatment initiated or maintained	112 (94.9)	35 (97.2)
Biologic therapy
Maintained or initiated at index date	75 (63.6)	14 (38.9)
Maintained	69 (58.5)	11 (30.6)
Initiated new	6 (5.1)	3 (8.3)
Naïve to biologics3	1 (0.8)	1 (2.8)
Discontinued at index date	0 (0.0)	0 (0.0)
Immunosuppressants
Maintained or initiated at index date	73 (61.9)	19 (52.8)
Maintained	71 (60.2)	14 (38.9)
Initiated new	2 (1.7)	5 (13.9)
Discontinued at index date	1 (0.8)	0 (0 .0)
5-ASA compounds
Maintained or initiated at index date	19 (16.1)	27 (75.0)
Maintained	17 (14.4)	20 (55.6)
Initiated new	2 (1.7)	5 (13.9)
Naïve to 5-ASA compounds	2 (1.7)	5 (13.9)
Discontinued at index date	1 (0.8)	0 (0.0)
Corticosteroids
Maintained or initiated at index date	16 (13.6)	15 (41.7)
Maintained	9 (7.6)	6 (16.7)
Initiated new	6 (5.1)	8 (22.2)
Naïve to corticosteroids3	2 (1.7)	1 (2.8)
Discontinued at index date	2 (1.7)	4 (11.1)
Any antibiotic initiated at index date	12 (10.2)	5 (13.9)
Treatment changes during 12-mo follow-up period
New treatment initiated during follow-up	77 (65.3)	31 (86.1)
Discontinuation or dose change during follow-up2	77 (68.1)	33 (94.3)
Median (IQR) number of treatment changes by patient	2 (2-5)	4 (3-7)
Biologic therapy
Initiated	45 (38.1)	6 (16.7)
Naïve to biologics4	13 (11.0)	1 (2.8)
Discontinued	23 (19.5)	5 (13.9)
Dose change	14 (11.9)	4 (11.1)
Immunosuppressants
Initiated	24 (20.3)	14 (38.9)
Naïve to immunosuppressants4	4 (3.4)	2 (5.6)
Discontinued	20 (16.9)	11 (9.3)
Dose change	7 (5.9)	7 (19.4)
5-ASA derivates
Initiated	10 (8.5)	21 (58.3)
Naïve to 5-ASA compounds4	1 (0.8)	2 (5.6)
Discontinued	7 (5.9)	8 (22.2)
Dose change	4 (3.4)	14 (38.8)
Corticosteroids
Initiated	24 (20.3)	16 (44.4)
Naïve to corticosteroids4	5 (4.2)	2 (5.6)
Discontinued	23 (19.5)	17 (47.2)
Any antibiotic initiated after index date	23 (19.5)	5 (13.9)

¹Inflammatory bowel disease (IBD) treatment patients were receiving at the time of enrollment, irrespective of the physician’s decision to continue or discontinue it at the end of the medical appointment.

²Percentages calculated from 113 Crohn’s disease and 35 ulcerative colitis patients, since two patients had no IBD medication and four had no medical appointments during follow-up.

³Assuming the information from the previous 3 year.

⁴Assuming the information from the previous 3 years and index date. Values are n (%), and percentages calculated within the total of the study population in each group, except if otherwise mentioned. SD: standard deviation; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; 5-ASA: 5-aminosalicylate.